Media

Media

GBT is a biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. The company has one FDA-approved therapy for sickle cell disease and one investigational therapy in development for the disease.

Recent News

DateTitle
03/17/20GBT Takes Steps to Support Public Health Efforts to Address COVID-19 Pandemic
03/04/20GBT Announces New Employment Inducement Grants
02/26/20GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2019 Financial Results
02/25/20GBT Announces Participation at the Cowen and Company 40th Annual Healthcare Conference

More »

Media Resources


Media Contact

Steven Immergut (media)
GBT
650-410-3258
media@gbt.com